- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 25
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 35
- States / cities
- Covina, California • Hemet, California • Los Angeles, California + 28 more
- Conditions
- Safety, Pharmacokinetics, Healthy Subjects
- Interventions
- Anifrolumab SC injection (300mg), Anifrolumab IV infusion (300mg), Anifrolumab SC infusion (600mg), Anifrolumab placebo SC injection (300mg), Anifrolumab placebo IV infusion (300mg), Anifrolumab placebo SC infusion (600mg)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
- Interventions
- anifrolumab, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Combination Product · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Covina, California • La Jolla, California + 28 more
- Conditions
- Systemic Sclerosis, Scleroderma
- Interventions
- Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label)
- Combination Product · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Chula Vista, California • Los Angeles, California + 23 more
- Conditions
- Polymyositis, Dermatomyositis
- Interventions
- Anifrolumab (blinded), Placebo, Anifrolumab (unblinded, open label)
- Combination Product · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Irvine, California • Aurora, Colorado + 38 more
- Conditions
- Lupus Nephritis
- Interventions
- LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA), corticosteroid
- Drug · Biological
- Lead sponsor
- Aurinia Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 27
- States / cities
- La Mesa, California • Los Alamitos, California • Arvada, Colorado + 23 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anifrolumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Female only
- Enrollment
- 442 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • El Cajon, California • Hemet, California + 50 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anifrolumab 300 mg, Anifrolumab 1000 mg, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • La Jolla, California • La Palma, California + 27 more
- Conditions
- Lupus Nephritis
- Interventions
- Anifrolumab, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • La Palma, California • Los Angeles, California + 13 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Cary, North Carolina
- Conditions
- Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Anifrolumab
- Combination Product · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 5 Years to 80 Years
- Enrollment
- 1,072 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Fort Lauderdale, Florida • Chicago, Illinois + 3 more
- Conditions
- Lupus Nephritis
- Interventions
- Anifrolumab, Placebo
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 17
- States / cities
- Glendale, Arizona • Phoenix, Arizona • La Jolla, California + 13 more
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Anifrolumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 68 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • La Palma, California • Long Beach, California + 19 more
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- Anifrolumab, Placebo
- Biological · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • El Cajon, California • La Jolla, California + 42 more
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Anifrolumab, Standard of Care
- Drug
- Lead sponsor
- Oklahoma Medical Research Foundation
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anifrolumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 30
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 23 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Anifrolumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Medi-546, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 27 more
- Conditions
- Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
- Interventions
- Anifrolumab
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Healthy Participants Study
- Interventions
- Anifrolumab, Autoinjector, Accessorized Pre-Filled Syringe
- Drug · Device
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland